Introduction Product Name Pimobendan CAS No. 74150-27-9 Synonyms (±)-UD CG 115BS; Pimobendane; 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone; 6-[2-(4-Methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one; 3(2H)-Pyridazinone, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl- Molecular Formula C19H18N4O2 Molecular Weight 334.37 MDL MFCD00226759 InChI 1/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24) Appearance White or slightly yellowish powder Property* Purity 99 % Density 1.36 g/cm3 Refractive Index n 20/D 1.692 *The values provided are general information and not part of the product specification. Application Main Applications Pimobendan is a calcium sensitizer with positive inotropic and vasodilator effects. It is also a selective inhibitor of phosphodiesterase III (PDE3). Pimobendan is used in the management of heart failure, most commonly caused by myxomatous mitral valve disease (also known as endocardiosis), or dilated cardiomyopathy. Packaging and Handling Grade Pharma Grade Packaging According to customer's request Storage and Transportation Storage in original sealed container. Recommended storage temperature: 4 °C. Protect from moisture, heat and foreign material.
used in the management of heart failure

CAS NO:74150-27-9

EC NO:

Molecular Formula:C₁₉H₁₈N₄O₂

Molecular Weight:334.37

Synonyms:;(±)-UD CG 115BS;2-(4-methoxyphenyl)-5(6)-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl)benzimidazole;3(2H)-pyridazinone, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-;3(2H)-pyridazinone, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-;4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone;6-[2-(4-Methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one;6-[2-(4-Methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one;UD CG 115 BS;pimobenda;

Molecular Structure: